


insights

Canada's voice for biotechnology /
Le porte-parole canadien de la biotechnologie



**CANADA COMPETES—
DESTINATION FOR BIOTECH
INVESTMENT AND TALENT**

**LE CANADA EN CONCURRENCE
À TITRE DE DESTINATION
POUR LES INVESTISSEMENTS
ET LES TALENTS EN BIOTECH**

The Biotech City

A unique hub in North America



CREATED IN 2001, LAVAL'S BIOTECH CITY HAS GROWN INTO A MAJOR BIOPHARMACEUTICAL AND LIFE SCIENCES CENTRE.

As it has for the better part of two decades, the Biotech City supports the creation and growth of companies focused on research and development. Today, Biotech City is home to more than 100 companies, directly employing more than 5,000 skilled workers.

Commissioner Jean-Marc Juteau says the strength of Biotech City lies in the integration of all phases of the life sciences sector: discovery, development, manufacturing and commercialization. "It is no coincidence that everything is in place to ensure the continuing success of the sector," he explains. "Certainly, the concentration of expertise contributes significantly to the success of the Biotech City. But equally important is the quality of the human resources available to companies in the Biotech City. This is due in

large part to the proximity of internationally recognized universities and research centres."

The Biotech City ecosystem is exceptionally diversified, thanks to the presence of biopharmaceutical, contract research organization (CRO), medical device, information technology, and nutraceutical companies. Multinationals such as Sanofi, GlaxoSmithKline, Servier, Bausch Health, and Roche Diagnostics also contribute to the success of the Biotech City.

CROs are especially important to development in the pharmaceutical industry. And the 18 CROs in the Biotech City provide considerable support for development, pre-clinical and clinical research. They contribute to the discovery of molecules, toxicity testing, pharmacokinetics, etc. Some of the most notable CROs are Altasciences, Citoxlab, Corealis, Cirion, Biotrial and Neomed Labs.

THE BIOTECH CITY AT A GLANCE:

- 5,000 people in more than 100 companies
- The National Institute for Scientific Research (INRS)
- The CQIB incubator
- 12,000,000 sqf dedicated to science and high technology
- 20 minutes from YUL airport
- Served by the Montreal subway

AREAS OF EXPERTISE:

- Biotechnology
- Pharmaceutical
- Contract Research Organization (CRO)
- Health Technology
- Nutraceutical

www.citebiotech.com

"It is no coincidence that everything is in place to ensure the continuing success of the sector."

Today, says Commissioner Juteau, Laval's Biotech City is a national force for biotechnology and life sciences. "Since 2001, more than \$4 billion in private funds has been invested for new construction, land purchase, equipment, research & development and training. As a result, an average of 275 new high-value jobs have been created in the hub every year."

While the Biotech City brings together a number of important companies, the National Institute for Scientific Research (INRS) is at the base of the bio-pharmaceutical development pyramid. M.Sc. and Ph.D. students and postdocs receive training in five programs in the fields of applied microbiology, experimental sciences of health, biology and virology and immunology. INRS also hosts the Doping Control Laboratory, recognized worldwide and accredited by the International Olympic Committee (IOC). In addition, the hub is home to the National Centre for Experimental Biology (CNBE), which specializes in exploratory studies in animals.

Located in the heart of the Biotech City, the Quebec Centre for Innovation in Biotechnology (CQIB) is a world-renowned incubator of life sciences. Since its creation in 1995, 55 companies have been incubated, resulting in the creation of more than 1,000 jobs. The CQIB offers incubated companies pharmaceutical grade laboratories that meet GLP and GMP standards. The incubator also supports entrepreneurs in their business development. Startups are put in contact with consultants and financing groups to ensure their growth and to ensure that they can, eventually, stand on their own. Foreign startups are also welcome.

But the Biotech City is not resting on its laurels. Plans are already under way for Phase II, the development of 1 million square feet of land within walking distance of the subway and downtown Laval. Officials hope Phase II will attract even more foreign companies and accommodate even more startups. 📍



Top: INRS-Institut Armand-Frappier

Middle: CQIB Incubator

Bottom: Corealis Pharma